Last reviewed · How we verify
MELAGATRAN
Melagatran is a marketed anticoagulant that specifically targets the factor Xa enzyme in the coagulation cascade. Its key strength lies in its precise mechanism of action, which can offer a targeted therapeutic approach to managing coagulation disorders. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | MELAGATRAN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
Common side effects
Key clinical trials
- Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MELAGATRAN CI brief — competitive landscape report
- MELAGATRAN updates RSS · CI watch RSS